Cisplatin Binding Sites on Human Albumin*
暂无分享,去创建一个
J Christodoulou | A I Ivanov | P J Sadler | P. Sadler | J. Christodoulou | A. Ivanov | J. Parkinson | K. Barnham | A. Tucker | J. Woodrow | K J Barnham | J A Parkinson | A Tucker | J Woodrow
[1] P. Kuchel,et al. Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione studied by 1H, 13C, 195Pt and 15N-{1H} DEPT NMR , 1990 .
[2] S. Lippard,et al. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. , 1996, Biochemistry.
[3] J. H. Viles,et al. Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins. Comparison with Co2+, Cd2+ and Al3+. , 1994, European journal of biochemistry.
[4] J. Keeler,et al. Minimizing Sensitivity Losses in Gradient-Selected 15N-1H HSQC Spectra of Proteins , 1994 .
[5] J. Verweij,et al. Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. , 1994, British Journal of Cancer.
[6] M. Aapro. Radiotherapy and drugs: 'setrons' once again. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] P. Sadler,et al. 1H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys34 , 1995, FEBS letters.
[8] P. Sadler,et al. Platination of a GG site on single-stranded and double-stranded forms of a 14-base oligonucleotide with diaqua cisplatin followed by NMR and HPLC -- influence of the platinum ligands and base sequence on 5'-G versus 3'-G platination selectivity. , 1997, European journal of biochemistry.
[9] H. Zeng,et al. FT-Raman studies on the transformation of G-actin to F-actin, the binding of cisplatin and transplatin to F-actin and the effects of the conformation of F-actin. , 1997, International journal of biological macromolecules.
[10] M. Yamamoto,et al. In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. , 1995, Journal of pharmaceutical sciences.
[11] L. Kèlland. Platinum anticancer drugs , 1994 .
[12] F. Gurd,et al. Nuclear magnetic resonance studies of sperm whale myoglobin specifically enriched with 13C in the methionine methyl groups. , 1976, The Journal of biological chemistry.
[13] N. Hadjiliadis,et al. NMR Study of the Interaction of Platinum Salts with a Tetrapeptide Containing Cysteinyl Residues , 1994 .
[14] T. Wright,et al. Interaction of natural and synthetic albumin polymers with hepatocytes , 1987, Hepatology.
[15] H. Ogata,et al. Decomposition Kinetics of Cisplatin in Human Biological Fluids , 1996, The Journal of pharmacy and pharmacology.
[16] P. Sadler,et al. Hydrolysis products of cisplatin: pKa determinations via[1H, 15N] NMR spectroscopy , 1992 .
[17] W. E. Lindup,et al. Cisplatin nephrotoxicity: decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. , 1994, Biochemical pharmacology.
[18] Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck. , 1992, British journal of clinical pharmacology.
[19] G. Berthon. Handbook of metal-ligand interactions in biological fluids, bioinorganic chemistry , 1995 .
[20] P. Sadler,et al. Solvolysis of cis-[Pt(NH3)2Cl2] in dimethyl sulphoxide and reactions of glycine with [PtCl3(Me2SO)]– as probed by 195Pt nuclear magnetic resonance shifts and 195Pt–15N coupling constants , 1977 .
[21] P. Sadler,et al. Effects of chemical shift anisotropy and 14N coupling on the 1H and 195Pt nuclear magnetic resonance spectra of platinum complexes , 1982 .
[22] R. Freeman. A handbook of nuclear magnetic resonance , 1987 .
[23] E. Espinosa,et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. , 1995, Lung cancer.
[24] K. Dardoufas,et al. Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine. , 1997, Journal of chemotherapy.
[25] R. Lange,et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). , 1973, Cancer research.
[26] Peter J. Sadler,et al. Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. , 1996, Inorganic chemistry.
[27] N. W. Flodin. Handbook of Metal-Ligand Interactions in Biological Fluids , 1996 .
[28] S. Ito,et al. Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfarin binding. , 1991, Chemical & pharmaceutical bulletin.
[29] E. W. Miles. Modification of histidyl residues in proteins by diethylpyrocarbonate. , 1977, Methods in enzymology.
[30] A phase II trial of cisplatin and interferon alpha 2b in patients with advanced bladder cancer. , 1997, American journal of clinical oncology.
[31] M. Friedman,et al. The effects of platinum complexes on seven enzymes. , 1979, Biochimica et biophysica acta.
[32] S. Pizzo,et al. Complexes of serum albumin and cis-dichlorodiammineplatinum (II). The role of cysteine 34 as a nucleophilic entering group and evidence for reaction between bound platinum and a second macromolecule. , 1983, The Journal of biological chemistry.
[33] P. Jocelyn. Spectrophotometric assay of thiols. , 1987, Methods in enzymology.
[34] P. Sadler,et al. Stabilization of monofunctional platinum–nucleotide adducts: reactions of N-acetyl-L-methionine complexes with guanosine 5′-monophosphate and guanylyl(3′–5′)guanosine , 1996 .
[35] S. Pizzo,et al. Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. , 1988, Journal of inorganic biochemistry.
[36] P. Sadler,et al. Studies of platinum(II) methionine complexes : metabolites of cisplatin , 1992 .
[37] B. Keppler. Metal complexes in cancer chemotherapy , 1993 .
[38] J. Schacht,et al. Diet is a risk factor in cisplatin ototoxicity , 1995, Hearing Research.
[39] S. Urien,et al. Drug Binding in Plasma , 1994, Clinical pharmacokinetics.
[40] Hans Robert Kalbitzer,et al. Distribution of chemical shifts in 1H nuclear magnetic resonance spectra of proteins , 1988 .
[41] A. Eastman. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1986, Biochemistry.
[42] D. Eisenberg,et al. PtCl24-: a methionine-specific label for protein crystallography. , 1969, Journal of molecular biology.
[43] P. Sadler,et al. Proton NMR studies of bovine serum albumin. Assignment of spin systems. , 1992, European journal of biochemistry.
[44] D C Carter,et al. Structure of serum albumin. , 1994, Advances in protein chemistry.
[45] W Wolf,et al. Preparation and metabolism of a cisplatin/serum protein complex. , 1980, Chemico-biological interactions.
[46] A. J. Shaka,et al. Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients , 1995 .
[47] S. Ito,et al. Disulfide bond cleavage of human serum albumin and alterations of its secondary structure by cis-diamminedichloroplatinum(II) , 1992 .
[48] P. Sadler,et al. Chelate-ring-opened adducts of[Pt(en)(Me-Mal-O,O′)](en = ethane-1,2-diamine,Me-Mal = 2-methylmalonate) with methionine derivatives:relevance to the biological activity of platinum anticanceragents , 1997 .
[49] Stephen B. Howell. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.
[50] A. Habeeb. [37] Reaction of protein sulfhydryl groups with Ellman's reagent. , 1972, Methods in enzymology.
[51] D. Carter,et al. Atomic structure and chemistry of human serum albumin , 1992, Nature.
[52] R. Borch,et al. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[53] J. Kuduk-Jaworska,et al. Impact of K2PtCl4 on the structure of human serum albumin and its binding ability of heme and bilirubin. , 1994, Journal of inorganic biochemistry.
[54] R. F. Chen,et al. Removal of fatty acids from serum albumin by charcoal treatment. , 1967, The Journal of biological chemistry.
[55] S. Pizzo,et al. Inactivation of the plasma protease inhibitor alpha 2-macroglobulin by the antitumor drug cis-dichlorodiamineplatinum(II). , 1981, The Journal of biological chemistry.
[56] D. Bowdler,et al. Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck. , 1991, British journal of clinical pharmacology.
[57] S. Aggarwal,et al. Cisplatin-induced inhibition of the calcium-calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distention , 1997, Cancer Chemotherapy and Pharmacology.
[58] M. Esposito,et al. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. , 1988, Anticancer Research.
[59] G. Falkson,et al. Neoadjuvant cisplatin plus ifosfamide in patients with stage IIB cervical cancer: a single center phase II study , 1997 .
[60] H. Pinedo,et al. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. , 1986, Clinical chemistry.
[61] C. Briand,et al. Influence of time and chloride ions on the interaction of cisplatin with human albumin in‐vitro , 1987, The Journal of pharmacy and pharmacology.
[62] N. Dodsworth,et al. Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation , 1996, Biotechnology and applied biochemistry.
[63] A. Jones,et al. Uptake and metabolism of polymerized albumin by rat liver. Role of the scavenger receptor. , 1988, Gastroenterology.